John Wiley & Sons The Art of Drug Synthesis Cover The Art of Drug Synthesis illustrates how chemistry, biology, pharmacokinetics, and a host of other .. Product #: 978-0-471-75215-8 Regular price: $139.25 $139.25 Auf Lager

The Art of Drug Synthesis

Johnson, Douglas S. / Li, Jie Jack (Herausgeber)

Wiley Series on Drug Synthesis

Cover

1. Auflage Juli 2007
296 Seiten, Hardcover
Handbuch/Nachschlagewerk

ISBN: 978-0-471-75215-8
John Wiley & Sons

Kurzbeschreibung

The Art of Drug Synthesis illustrates how chemistry, biology, pharmacokinetics, and a host of other disciplines come together to produce successful medicines. The authors have compiled a collection of 21 representative categories of drugs, from which they have selected as examples many of the best-selling drugs on the market today. An introduction to each drug is provided, as well as background to the biology, pharmacology, pharmacokinetics, and drug metabolism, followed by a detailed account of the drug synthesis. Edited by prominent scientists working in drug discovery for Pfizer, this book meets the needs of a growing community of researchers in pharmaceutical R&D, providing a useful guide for practicing pharmaceutical scientists as well as a text for medicinal chemistry students. It provides an excellent follow-up to the very successful first book by these editors, Contemporary Drug Synthesis, but with all new therapeutic categories and drugs discussed.

Weitere Versionen

epubmobipdf

DISCOVER THE INS ANDOUTS OF DRUG SYNTHESIS, FROM IDENTIFYING A LEAD MOLECULE TO COMMERCIAL PRODUCTION.

Learn how chemistry, biology, pharmacokinetics, and a host of other disciplines all play a role in the successful discovery of new drugs and therapeutics. This text features contributions from seventeen leading medicinal and process chemists who show you how it is done. Some of the contributors were instrumental in the discovery of the drugs they review, offering you a unique and invaluable perspective on the complete drug discovery process.

The first two chapters of this text introduce the stringent requirements for a potential therapeutic molecule, approaches in finding molecular structures that 'hit" a biological target, and the many steps needed to go from initial small-scale laboratory synthesis to commercial and the many steps needed to go from initial small-scale laboratory synthesis to commercial production. The remaining fifteen chapters are divided into three major therapeutic areas:
* Cancer and infectious Diseases
* Cardiovascular and Metabolic Diseases
* Central Nervous System Diseases

These three section collectively cover twenty-one categories of drugs and more than sixty individual drugs, highlighting both medicinal and process synthetic routes. The authors present detailed accounts of the synthesis of such high-profile drugs as Actos(r), Levaquin(r), Avelox(r), Diflucan(r), Tamiflu(r), Zetia(r), Lyrica(r), and Strattera(r). You gain new insight into how a first generational agent is refined and improved by the application of medicinal chemistry for the discovery of second and third generation medicines.

This text is an excellent companion to the bestselling Contemporary Drug Synthesis, covering all new drugs. In addition to serving as a reference for medicinal chemists and pharmacologists, this book is highly recommended as a graduate-level text for medicinal pharmacologists, this book is highly recommended as a graduate-level text for medicinal and pharmaceutical chemistry courses. With its many examples and insights into successful and pharmaceutical chemistry courses. With its many examples and insights into successful syntheses, it enables students to make the bridge from theory to practice.

Foreword.

Preface.

Contributors.

1 THE ROLE OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY (John A. Lowe, III).

References.

2 PROCESS RESEARCH: HOW MUCH? HOW SOON? (Neal G. Anderson).

References.

I CANCER AND INFECTIOUS DISEASES.

3 AROMATASE INHIBITORS FOR BREAST CANCER: EXEMESTANE (AROMASIN), ANASTROZOLE (ARIMIDEX), AND LETROZOLE (FEMARA) (Jie Jack Li).

References.

4 QUINOLONE ANTIBIOTICS: LEVOFLOXACIN (LEVAQUIN), MOXIFLOXACIN (AVELOX), GEMIFLOXACIN (FACTIVE), AND GARENOXACIN (T-3811) (Chris Limberakis).

References.

5 TRIAZOLE ANTIFUNGALS: ITRACONAZOLE (SPORANOX), FLUCONAZOLE (DIFLUCAN), VORICONAZOLE (VFEND), AND FOSFLUCONAZOLE (PRODIF) (Andrew S. Bell).

References.

6 NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS (Arthur Harms).

References.

7 NEURAMINIDASE INHIBITORS FOR INFLUENZA: OSELTAMIVIR PHOSPHATE (TAMIFLU) AND ZANAMIVIR (RELENZA) (Douglas S. Johnson and Jie Jack Li).

References.

II CARDIOVASCULAR AND METABOLIC DISEASES.

8 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2 DIABETES (Jin Li).

References.

9 ANGIOTENSIN AT1 ANTAGONISTS FOR HYPERTENSION (Larry Yet).

References.

10 LEADING ACE INHIBITORS FOR HYPERTENSION (Victor J. Cee and Edward J. Olhava).

References.

11 DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION (Daniel P. Christen).

References.

12 SECOND-GENERATION HMG-CoA REDUCTASE INHIBITORS (Jeffrey A. Pfefferkorn).

References.

13 CHOLESTEROL ABSORPTION INHIBITORS: EZETIMIBE (ZETIA) (Stuart B. Rosenblum).

References.

III CENTRAL NERVOUS SYSTEM DISEASES.

14 DUAL SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SSNRIs) FOR DEPRESSION (Marta Piñeiro-Núñez)

References.

15 GABAA RECEPTOR AGONISTS FOR INSOMNIA: ZOLPIDEM (AMBIEN), ZALEPLON (SONATA), ESZOPICLONE (ESTORRA, LUNESTA), AND INDIPLON (Peter R. Guzzo).

References.

16 a2d LIGANDS: NEURONTIN (GABAPENTIN) AND LYRICA (PREGABALIN) (Po-Wai Yuen).

References.

17 APPROVED TREATMENTS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: AMPHETAMINE (ADDERALL), METHYLPHENIDATE (RITALIN), AND ATOMOXETINE (STRATERRA) (David L. Gray).

References.

Index.
Douglas S. Johnson, PHD, is a Research Chemist at Pfizer Global Research and Development.

Jie Jack Li, PHD, is a Research Chemist at Pfizer Global Research and Development.

D. S. Johnson, Pfizer Global Research and Development; J. J. Li, Pfizer Global Research and Development